← FDA Drug Approvals (Drugs@FDA)

ERIBULIN MESYLATE

ANDA · Abbreviated New Drug Application (Generic) · Sponsor: NATCO · Approved 2026-06-01

Drug application

FDA Application #

ANDA217085

Application type

Abbreviated New Drug Application (Generic)

Brand name

ERIBULIN MESYLATE

Generic name

Eribulin Mesylate

Active ingredients

ERIBULIN MESYLATE

Dosage form

SOLUTION

Route

INTRAVENOUS

Marketing status

Prescription

Sponsor

NATCO

First approval

2026-06-01

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown